RILEY WILLMAN: Open Payments
NPI 1043859267 · SCOTTSDALE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,325 in 89 payments from 17 companies in 2025. Trend: 2023 $1,208 · 2024 $2,306 · 2025 $2,325
Food & beverage: $2,325
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $376 |
| GlaxoSmithKline, LLC. | 23 | $365 |
| CSL Behring | 11 | $329 |
| GENZYME CORPORATION | 13 | $232 |
| Novartis Pharmaceuticals Corporation | 7 | $215 |
| Grifols USA, LLC | 8 | $179 |
| Organon LLC | 3 | $172 |
| Octapharma USA, Inc. | 1 | $90 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $86 |
| BioCryst US Sales Co., LLC | 3 | $63 |
Products named: NUCALA, Hizentra, Rhapsido, BREZTRI, Xembify, DUPIXENT, VTAMA, AYVAKIT.
Industry payments across AZ — which companies pay providers there.
